AI Article Synopsis
- Precision oncology (PO) in Italy has faced challenges due to a top-down implementation by regional health institutions, leading to inefficiencies and unequal patient access.
- A collaborative bottom-up approach was tested among healthcare professionals and institutions to enhance PO delivery by observing practices across various health care authorities.
- The study produced 14 consensus statements aiming to address key issues and promote uniform integration of PO within the national healthcare system, highlighting the need for collaboration among professionals and organizations.
Article Abstract
Purpose: Precision oncology (PO) promises positive results for patients. To date, in Italy, the effort to implement PO has been made autonomously by regional health institutions in a top-down fashion. This approach is not very efficient and jeopardizes patients' equal access to PO. Similar outcomes have been recorded in other Western countries. We tested a method of collaboration among professionals, scientific societies, and government institutions to facilitate the delivery of PO innovation to patients' bedsides.
Method: We designed an organizational research project on the basis of a bottom-up approach. We started by observing PO-related activities in five health care authorities (HCAs) in one Italian region. We then compared the issues that emerged with those of three additional HCAs in other Italian regions. Using the results of the initial observation and adopting validated multiple-step consensus methods, we finally derived 14 statements that were approved by the four main scientific societies of oncology and pathology at the national level.
Results: The 14 statements addressed the main issues linked to the implementation of PO in clinical practice. The strong professional consensus advocated for prompt adoption within the national healthcare system.
Conclusions: The consensus on the statements that were obtained shows the importance of a synergistic effort among professionals, scientific societies, and health care institutions in defining homogeneous solutions for innovation implementation within the health care system.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645411 | PMC |
| http://dx.doi.org/10.1200/PO.23.00166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clarity unveiled: A journey through time in cataract surgery.
J Perioper Pract
January 2025
University of Derby, Derby, UK.
This historical research article offers a comprehensive examination of the evolution of cataract surgery from ancient practices to modern innovations. The historical trajectory of cataract treatment will be explored, beginning with ancient techniques such as couching in ancient civilisations and progressing through critical milestones in surgical advancement. The research delves into the challenges faced by early practitioners, the emergence of novel techniques and the pivotal contributions of pioneering surgeons throughout history.
View Article and Find Full Text PDFClinical, Diagnostic and Therapeutic Framework of mHSPC and nmCRPC: A Multidisciplinary Consensus Project of the Italian Society for Uro-Oncology (SIUrO).
Clin Genitourin Cancer
December 2024
Medical and Translational Oncology, Department of Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy.
The recent evidences provided in metastatic hormone sensitive prostate cancer (nmHSPC) and in nonmetastatic castration resistant (nmCRPC) introduced the possibility to adopt Androgen Receptor Signaling inhibitor (ARSi) alone (both settings) or with chemotherapy (in mHSPC). In daily clinical practice there are some opening questions regarding the inclusion of next generation imaging, mainly PSMA-PET, how integrate local treatment as radiotherapy, how to select patients or drugs in a multiple-choice scenario, and how to manage patients with comorbidities and polypharmacy. These issues led the Italian Society for Uro-Oncology (SIUrO) to develop a consensus project involving all of the most important Italian scientific societies engaged in the multidisciplinary and multiprofessional management of the disease.
View Article and Find Full Text PDFEBSA at 40 - an updated history.
Eur Biophys J
January 2025
Biochemistry Department, South Parks Road, Oxford, OX1 3QU, UK.
The European Biophysical Societies' Association (EBSA) is an association of 32 biophysical societies in Europe dedicated to the promotion of excellence in biophysics. Through cooperation and collaborative activities, EBSA makes a major and positive impact on the European and International biophysics community. Biennial congresses at various European locations, organized by host societies, are a major activity that engages biophysicists with the wider international scientific community.
View Article and Find Full Text PDFHow We Treat ANCA-Associated Vasculitis: A Focus on the Maintenance Therapy.
J Clin Med
January 2025
University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, ASL Città di Torino and University of Torino, 10154 Turin, Italy.
Recent progress has notably improved outcomes for patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), namely granulomatosis with polyangiitis and microscopic polyangiitis. Since 2021, several international scientific societies have recommended rituximab (RTX) as the preferred primary treatment for maintaining remission in AAV patients. Decisions regarding retreatment with RTX are based on individual patient risk factors for disease flare-ups and the potential consequences of such flares.
View Article and Find Full Text PDFNutraceuticals and Supplements in Management of Prediabetes and Diabetes.
Nutrients
December 2024
SINut-Società Italiana di Nutraceutica, Via Guelfa, 9, 40138 Bologna, Italy.
Dysglycemia is a condition preceding diabetes mellitus. The two situations inherent in this condition are called impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). If one of these situations is found in the patient, after the advice of an appropriate diet and physical activity, the addition of nutraceuticals or supplements can be considered, which can stop or delay the progression to diabetes mellitus over time.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!